TRU

PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

nd to a collection of information unless it displays a valid OMR control number

	Application Number	10/684,532
TRANSMITTAL	Filing Date	October 15, 2003
FORM	First Named Inventor	Karl GUEGLER / W
(to be used for all correspondence after initial fil	ng) Art Unit	1649 (2 DEC 1 9 2005)
	Examiner Name	John D. ULM
	Attorney Docket Number	CL000861CON
Total Number of Pages in This Submission		
ENCLOSURES (Check all that apply)		
Fee Transmittal Form	Drawing(s)	After Allowance communication to Technology Center (TC)
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC
Amendment/Reply	Petition	(Appeal Notice, Brief, Reply Brief)
After Final	Petition to Convert to a Provisional Application	Proprietary Information
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Add	ress Status Letter
Extension of Time Request	Terminal Disclaimer	Other Enclosure(s) (please Identify below):
	Request for Refund	1). 2 Cited References
Express Abandonment Request		
Information Disclosure Statement	CD, Number of CD(s)	
Certified Copy of Priority Document(s)		
Response to Missing Parts/		
Incomplete Application		
Response to Missing Parts		
under 37 CFR 1.52 or 1.53		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or		
Individual name Peter Tung, Reg. No. 51, 269		
Signature Lete Drug		
Date December 19, 2005		
CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with		
sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name		
Signature		Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



In re Application of: Guegler et al.

Art Unit: 1649

Serial No. 10/684,532

Examiner: John Ulm

Filed: October 15, 2003

Atty. Docket: CL00861CON

For: ISOLATED HUMAN TRANSPORTER PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN TRANSPORTER PROTEINS, AND USES THEREOF

Amendment and Reply Under 37 C.F.R. 1.111

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Reply is in response to the Office Action by Examiner John Ulm, mailed September 19, 2005. Applicants request reconsideration of the above-referenced patent application in view of the following remarks. It is believed that no fees are due with this reply. However, if the Office determines that fees are due to prevent abandonment of this application, the Office is hereby authorized to charge any fees that are due related to the present application to Deposit Account No. 50-0970.

Please amend the application as follows: